Cargando…

Does rapid HIV disease progression prior to combination antiretroviral therapy hinder optimal CD4(+) T-cell recovery once HIV-1 suppression is achieved?

OBJECTIVE: This article compares trends in CD4(+) T-cell recovery and proportions achieving optimal restoration (≥500 cells/μl) after viral suppression following combination antiretroviral therapy (cART) initiation between rapid and nonrapid progressors. METHODS: We included HIV-1 seroconverters ach...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jarrin, Inma, Pantazis, Nikos, Dalmau, Judith, Phillips, Andrew N., Olson, Ashley, Mussini, Cristina, Boufassa, Faroudy, Costagliola, Dominique, Porter, Kholoud, Blanco, Juliá, Del Amo, Julia, Martinez-Picado, Javier
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2015
Materias:	Epidemiology and Social
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5629982/ https://www.ncbi.nlm.nih.gov/pubmed/26544704 http://dx.doi.org/10.1097/QAD.0000000000000805

Ejemplares similares

The impact of transient combination antiretroviral treatment in early HIV infection on viral suppression and immunologic response in later treatment
por: Pantazis, Nikos, et al.
Publicado: (2016)

Blunted Response to Combination Antiretroviral Therapy in HIV Elite Controllers: An International HIV Controller Collaboration
por: Boufassa, Faroudy, et al.
Publicado: (2014)

Symptomatic Illness and Low CD4 Cell Count at HIV Seroconversion as Markers of Severe Primary HIV Infection
por: Lodi, Sara, et al.
Publicado: (2013)

Antiretroviral therapy for HIV controllers: Reasons for initiation and outcomes in the French ANRS-CO21 CODEX cohort
por: Plaçais, Léo, et al.
Publicado: (2021)

Beyond viral suppression of HIV – the new quality of life frontier
por: Lazarus, Jeffrey V., et al.
Publicado: (2016)

Limiting Cumulative HIV Viremia Copy-Years by Early Treatment Reduces Risk of AIDS and Death
por: Olson, Ashley D., et al.
Publicado: (2016)

Kaposi Sarcoma Incidence and Survival Among HIV-Infected Homosexual Men After HIV Seroconversion
por: Lodi, Sara, et al.
Publicado: (2010)

CASCADE protocol: exploring current viral and host characteristics, measuring clinical and patient-reported outcomes, and understanding the lived experiences and needs of individuals with recently acquired HIV infection through a multicentre mixed-methods observational study in Europe and Canada
por: Ruiz-Burga, Elisa, et al.
Publicado: (2023)

Detectable HIV-RNA in semen of HIV controllers
por: Chaix, Marie-Laure, et al.
Publicado: (2017)

Development of an oral once-weekly drug delivery system for HIV antiretroviral therapy
por: Kirtane, Ameya R., et al.
Publicado: (2018)

Are European HIV cohort data within EuroCoord representative of the diagnosed HIV population?
por: Vourli, Georgia, et al.
Publicado: (2019)

Choice of the initial antiretroviral treatment for HIV-positive individuals in the era of integrase inhibitors
por: Alejos, Belén, et al.
Publicado: (2019)

Post-Treatment HIV-1 Controllers with a Long-Term Virological Remission after the Interruption of Early Initiated Antiretroviral Therapy ANRS VISCONTI Study
por: Sáez-Cirión, Asier, et al.
Publicado: (2013)

Persistent HIV-1 replication during antiretroviral therapy
por: Martinez-Picado, Javier, et al.
Publicado: (2016)

Pretreatment CD4 Cell Slope and Progression to AIDS or Death in HIV-Infected Patients Initiating Antiretroviral Therapy—The CASCADE Collaboration: A Collaboration of 23 Cohort Studies
por: Wolbers, Marcel, et al.
Publicado: (2010)

Clinical Progression Rates by CD4 Cell Category Before and After the Initiation of Combination Antiretroviral Therapy (cART)
por: Guiguet, Marguerite, et al.
Publicado: (2008)

Dynamics in HIV‐DNA levels over time in HIV controllers
por: Avettand‐Fenoel, Véronique, et al.
Publicado: (2019)

Potential Role for HIV-Specific CD38(−)/HLA-DR(+) CD8(+) T Cells in Viral Suppression and Cytotoxicity in HIV Controllers
por: Hua, Stéphane, et al.
Publicado: (2014)

A Subset of Extreme Human Immunodeficiency Virus (HIV) Controllers Is Characterized by a Small HIV Blood Reservoir and a Weak T-Cell Activation Level
por: Canouï, Etienne, et al.
Publicado: (2017)

TB testing in HIV-positive patients prior to antiretroviral treatment
por: Spooner, E., et al.
Publicado: (2022)

Overall and cause-specific excess mortality in HIV-positive persons compared with the general population: Role of HCV coinfection
por: Alejos, Belén, et al.
Publicado: (2016)

Impact of co-infection by hepatitis C virus on immunological and virological response to antiretroviral therapy in HIV-positive patients
por: Portocarrero Nuñez, Julian Alexander, et al.
Publicado: (2018)

557. Evaluation of Clinical Response of a Two Tablet Once Daily Antiretroviral Regimen in Antiretroviral Experienced HIV-Infected Patients
por: Maki, Gina, et al.
Publicado: (2018)

Increasing contribution of integrated forms to total HIV DNA in blood during HIV disease progression from primary infection
por: Trémeaux, Pauline, et al.
Publicado: (2019)

HIV-1 integrase polymorphisms are associated with prior antiretroviral drug exposure
por: van Hal, Sebastiaan J, et al.
Publicado: (2009)

Analysis of NKp30/NCR3 isoforms in untreated HIV-1-infected patients from the ANRS SEROCO cohort
por: Prada, Nicole, et al.
Publicado: (2013)

395 Hindering Generic Antiretroviral Treatment Competition for Human Immunodeficiency Virus: Anti-Competitive Agreements and HIV Disease Management Concerns
por: Crovetto, Arianna
Publicado: (2023)

Immunologic and Virologic Progression in HIV Controllers: The Role of Viral “Blips” and Immune Activation in the ANRS CO21 CODEX Study
por: Noel, Nicolas, et al.
Publicado: (2015)

Temporal Trends and Geographic Variability in the Prescription of Antiretroviral Treatments in People Living with HIV in Spain, 2004–2020
por: Ruiz-Algueró, Marta, et al.
Publicado: (2022)

Dendritic Cells from HIV Controllers Have Low Susceptibility to HIV-1 Infection In Vitro but High Capacity to Capture HIV-1 Particles
por: Hamimi, Chiraz, et al.
Publicado: (2016)

Virologic and Immunologic Response to cART by HIV-1 Subtype in the CASCADE Collaboration
por: Touloumi, Giota, et al.
Publicado: (2013)

CD4 Dynamics over a 15 Year-Period among HIV Controllers Enrolled in the ANRS French Observatory
por: Boufassa, Faroudy, et al.
Publicado: (2011)

Disease progression and mortality with untreated HIV infection: evidence synthesis of HIV seroconverter cohorts, antiretroviral treatment clinical cohorts and population‐based survey data
por: Glaubius, Robert, et al.
Publicado: (2021)

Distinct Genetic Loci Control Plasma HIV-RNA and Cellular HIV-DNA Levels in HIV-1 Infection: The ANRS Genome Wide Association 01 Study
por: Dalmasso, Cyril, et al.
Publicado: (2008)

Differences in HIV Natural History among African and Non-African Seroconverters in Europe and Seroconverters in Sub-Saharan Africa
por: Pantazis, Nikos, et al.
Publicado: (2012)

High Antibody-Dependent Cellular Cytotoxicity Responses Are Correlated with Strong CD8 T Cell Viral Suppressive Activity but Not with B57 Status in HIV-1 Elite Controllers
por: Lambotte, Olivier, et al.
Publicado: (2013)

HIV-Specific B Cell Frequency Correlates with Neutralization Breadth in Patients Naturally Controlling HIV-Infection
por: Rouers, Angeline, et al.
Publicado: (2017)

Toward an understanding of when prior knowledge helps or hinders learning
por: Brod, Garvin
Publicado: (2021)

Twice-daily versus once-daily antiretroviral therapy and coformulation strategies in HIV-infected adults: benefits, risks, or burden?
por: Nachega, Jean B, et al.
Publicado: (2011)

Efficacy, Safety and Pharmacokinetics of Once-Daily Saquinavir Soft-Gelatin Capsule/Ritonavir in Antiretroviral-Naive, HIV-Infected Patients
por: Julio, Montaner SG, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_u7sulgp51i4l3v7nn4hhevbthe